News | Stroke | June 28, 2023

U-shaped Association Between Low-density Lipoprotein Cholesterol Levels and Risk of All-cause Mortality Mediated by Post-stroke Infection in Acute Ischemic Stroke

This study aimed to evaluate the association between LDL-C levels, post-stroke infection and all-cause mortality. 804,855 ischemic stroke patients were enrolled.

The U-shaped association between LDL-C level and all-cause mortality during hospitalization, and the mediation effect of infection in patients with acute ischemic stroke in the CSCA program. 804,855 patients were included. Abbreviations: LDL-C: low-density lipoprotein cholesterol; CSCA: Chinese Stroke Center Alliance. Image courtesy of Science China Press 


June 28, 2023 — The general perception supports the mantra of “lower is better” for low-density lipoprotein cholesterol (LDL-C) levels in cardiovascular disease. However, during the acute stage of ischemic stroke, it is unclear how to interpret different LDL-C levels accurately. The evidence on clinical implication of LDL-C levels was mainly derived from long-term follow-up studies. The pathophysiological features of patients under the acute stage of ischemic stroke are different from the chronic stage. Concerns exist over whether low LDL-C levels may lead to adverse outcomes, such as increased mortality risk due to infection. The crosstalk between LDL-C and infection is also garnering increasing amounts of interest. 

This study aimed to evaluate the association between LDL-C levels, post-stroke infection and all-cause mortality. 804,855 ischemic stroke patients were enrolled. Associations between LDL-C levels, infection, and mortality risk were estimated by multivariate logistic regression models. Mediation analysis was performed under counterfactual framework to elucidate the mediation effect of post-stroke infection. 

The study found a U-shaped association between LDL-C and mortality risk in acute ischemic stroke patients. The lowest mortality risk was at an LDL-C level of 2.67 mmol/L. The association between LDL-C and all-cause mortality was 38.20% mediated by infection. Sensitivity analysis showed that after excluding patients with increasing numbers of cardiovascular risk factors, the U-shaped association remained consistent but the LDL-C interval with the lowest mortality risk increased progressively, where infection maintained prominent mediation effects. Subgroup analysis showed a consistent U-shaped association between LDL-C levels and mortality risk. The mediation effects of infection were largely consistent in subgroups of age ≥65 years, female, body mass index <25 kg/m2, and National Institutes of Health Stroke Scale ≥16. 

Despite the known adverse effects of high LDL-C levels, in ischemic stroke patients, this study revealed that low LDL-C levels also indicate an increased risk of all-cause mortality during hospitalization, where post-stroke infection is an important mediating mechanism, indicating a potential causal chain of low LDL-C-infection-mortality in the acute stage of ischemic stroke. Further research is warranted to explore the risk-benefit relationship of approaches for rapid and substantial LDL-C reduction during the acute stage of ischemic stroke. 

For more information: https://www.scichina.com/


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now